Cesca Therapeutics Highlights Promising Data for the Treatment of Chronic Non-Healing Ulcers
March 15 2017 - 5:00AM
Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated
cell processing and point-of-care autologous cell-based therapies,
today announced encouraging data from a study evaluating the use of
autologous platelet rich plasma (PRP) for the treatment of chronic
non-healing ulcers.
Results from the 24 patient study entitled
“Treatment of chronic non-healing ulcers using autologous platelet
rich plasma: a case series” were published in the peer-reviewed,
Journal of Biomedical Science. The study was led by researchers
from TotipotentRX, a subsidiary of Cesca Therapeutics, and Fortis
Memorial Research Institute.
In the study, 24 patients with one wound/ulcer
of varying etiology were treated with a single dose of PRP
injections around the wound alongside a topical administration of
autologous platelet gel. The process was completed at the patient’s
bedside in a single session within 30 minutes. Healing of the
wound/ulcer was observed in patients as early as 4 weeks after the
PRP treatment with a mean healing time of 8.2 weeks ±1.9. All
patients demonstrated healing of the wound/ulcer, with 17 (70.8%)
patients showing a 90% reduction in wound size and 3 (12.5%)
patients showing an 80-90% reduction over the course of the 24 week
follow-up. The study also reported that there were no adverse
events on the day of treatment or during the patient’s 24 week
follow-up, demonstrating a good safety profile for the treatment of
chronic non-healing wounds/ulcers.
Dr. Venkatesh Ponemone, Study Director and
Executive Director of TotipotentRX commented, “We are very pleased
with the data from the study and believe that the use of PRP is a
major breakthrough for the treatment of chronic non-healing wounds
and ulcers. Using Cesca’s point-of-care platform, we are able to
develop rapid cell based therapies at the patient’s bedside within
30 minutes significantly reducing the risk and costs associated
with current standard of care treatments."
“This peer-reviewed publication further
validates our novel point-of-care platform for rapid cellular based
therapies,” commented Dr. Chris Xu, Cesca's Interim Chief Executive
Officer. “As we continue to strengthen our team and evaluate
Cesca’s clinical pipeline, these additional data points serve as
useful litmus tests to determine the most valuable growth
opportunities for the company.”
Chronic non-healing ulcers pose a significant
health risk worldwide affecting an estimated 2-6 million people in
the United States alone, and are a major cause of non-traumatic
lower limb amputations. Despite a variety of standard of care
treatments, many chronic ulcers fail to heal or persist for
months/years and/or recur after healing, requiring additional
advanced wound care therapies. Platelet Rich Plasma, however, has
been a major breakthrough in the arena of vascular therapies
allowing the use of a patient’s own body cells for wound/ulcer
treatment, providing the necessary growth factors that enhance
tissue healing.
About Cesca Therapeutics Inc.Cesca Therapeutics
Inc. (www.cescatherapeutics.com) is engaged in the research,
development, and commercialization of cellular therapies and
delivery systems for use in regenerative medicine. The Company is a
leader in the development and manufacture of automated blood and
bone marrow processing systems that enable the separation,
processing and preservation of cell and tissue therapeutics. These
include:
- The SurgWerks™ System (in development) -- a
proprietary system comprised of the SurgWerks Processing Platform,
including devices and analytics, and indication-specific SurgWerks
Procedure Kits for use in regenerative stem cell therapy at the
point-of-care for vascular and orthopedic diseases.
- The CellWerks™ System (in development) -- a
proprietary cell processing system with associated analytics for
intra-laboratory preparation of adult stem cells from bone marrow
or blood.
- The AutoXpress® System (AXP®) -- a
proprietary automated device and companion sterile disposable for
concentrating hematopoietic stem cells from cord blood.
- The MarrowXpress™ System
(MXP™) -- a derivative product of the AXP and its accompanying
sterile disposable for the isolation and concentration of
hematopoietic stem cells from bone marrow.
- The BioArchive® System -- an automated
cryogenic device used by cord blood banks for the cryopreservation
and storage of cord blood stem cell concentrate for future
use.
- Manual bag sets for use in the processing and
cryogenic storage of cord blood.
Forward-Looking StatementThe
statements contained herein may include statements of future
expectations and other forward-looking statements that are based on
management’s current views and assumptions and involve known and
unknown risks and uncertainties that could cause actual results,
performance or events to differ materially from those expressed or
implied in such statements. A more complete description of risks
that could cause actual events to differ from the outcomes
predicted by Cesca Therapeutics' forward-looking statements is set
forth under the caption "Risk Factors" in Cesca Therapeutics annual
report on Form 10-K and other reports it files with the Securities
and Exchange Commission from time to time, and you should consider
each of those factors when evaluating the forward-looking
statements.
Company Contact: Cesca Therapeutics Inc.
ir@cescatherapeutics.com
Investor Contact: The Ruth Group
Lee Roth / Tram Bui
646-536-7012 / 7035
lroth@theruthgroup.com / tbui@theruthgroup.com
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From Apr 2024 to May 2024
Cesca Therapeutics (NASDAQ:KOOL)
Historical Stock Chart
From May 2023 to May 2024